Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmunes expectations for the its Scientific Advisory Board; Aimmunes expectations for its Phase 3 trials of AR101, including PALISADE, RAMSES and ARTEMIS; Aimmunes expectations regarding the potential benefits of AR101; and Aimmunes expectations regarding potential applications of the CODIT approach to treating life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the expectation that Aimmune will need additional funds to finance its operations; the companys ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; the possibility that Aimmunes clinical trials will not be successful; Aimmunes dependence on the success of AR101; the companys reliance on third parties for the manufacture of the companys product candidates; possible regulatory developments in the United States and foreign countries; and the companys ability to attract and retain senior management personnel. These and other risks and uncertainties are described more fully in Aimmune’s most recent filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).https://youtube.com/watch?feature=player_embedded&v=Pf7JuJcVzQU
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/aimmune-therapeutics-appoints-scientific-advisory-120000190.html
Medscape Medical News, October 05, 2016 Breast Cancer Deaths Increasing for Black Women Researchers have known for years that African-American women die of breast cancer at higher rates than white women. WebMD Health News, October 05, 2016 Head-to-Head Results Compare biologic for Psoriasis For patients with moderate to severe plaque psoriasis, ixekizumab is more effective than ustekinumab at 12 weeks, researchers report, but a longer-term study is needed to confirm this. see hereIt is a ladder-through programme, meaning that the years of training run continuously, dependent on satisfactory progression. comfortable with an informal and flexible environment? someone who thrives in a team situation? View the available trials. In some jurisdictions, paediatric training is begun immediately following completion of entry-level training. paediatricians often have to treat the parents and sometimes, the family, rather than just the child.